Biocept, Inc. (BIOCQ)

OTCMKTS · Delayed Price · Currency is USD
0.0001
-0.0019 (-95.00%)
Dec 4, 2025, 4:00 PM EST
-0.00%
Market Cap 263.00
Revenue (ttm) 1.36M
Net Income (ttm) -30.61M
Shares Out 2.63M
EPS (ttm) -44.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,079
Average Volume 2,600
Open 0.0001
Previous Close 0.0020
Day's Range 0.0001 - 0.0001
52-Week Range 0.0000 - 0.1000
Beta -17.67
RSI 47.17
Earnings Date n/a

About Biocept

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications... [Read more]

Sector Healthcare
Founded 1997
Employees 50
Stock Exchange OTCMKTS
Ticker Symbol BIOCQ
Full Company Profile

Financial Performance

In 2022, Biocept's revenue was $25.86 million, a decrease of -57.78% compared to the previous year's $61.25 million. Losses were -$32.09 million, 1036.2% more than in 2021.

Financial Statements

News

There is no news available yet.